GLENMARK PHARMACEUTICALS LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,220 INR | -0.87% |
|
-1.85% | +42.85% |
| 06-12 | India Equities Close Higher Ahead of US Inflation Data | MT |
| 06-12 | Glenmark Pharmaceuticals Gets US FDA Final Nod for Esomeprazole Magnesium Capsules | MT |
Presenter SpeechUtkarsh Gandhi (Executives)Good evening, everyone. Thank you. Thank you for jo...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Glenmark Pharmaceuticals Limited is an India-based global pharmaceutical company. The Company is focused on building a global formulation business with branded, generics and over the counter (OTC) segments in the therapy areas of dermatology, respiratory and oncology. The Company also has a regional/country-specific presence in other therapeutic areas like diabetes, cardiovascular and oral contraceptives. Its product portfolio includes topical products, liquids, respiratory MDI/DPI, complex injectables and biologics, and oral solids. The Company has a bioequivalent version of Tiotropium Bromide dry powder inhaler (DPI) under the brand, Tiogiva in the United Kingdom and Tavulus in Spain, for the treatment of chronic obstructive pulmonary disease. Ryaltris, the Company's first branded specialty product globally, is a fixed dose combination nasal spray that combines an antihistamine (Olopatadine) with a steroid (Mometasone Furoate) for treatment of allergic rhinitis.
Sector
Pharmaceuticals
Calendar
2024-08-08
- Q1 2025 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
13
Last Close Price
1,231
INR
Average target price
1,110
INR
Spread / Average Target
-9.79%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +42.85% | 4.15B | |
| +18.66% | 42.12B | |
| +23.31% | 21.72B | |
| +20.71% | 14.89B | |
| +56.75% | 13.06B | |
| -0.05% | 6.79B | |
| -12.68% | 6.3B | |
| +20.03% | 6.05B | |
| -8.87% | 5.73B | |
| +6.29% | 4.58B |
- Stock Market
- Equities
- GLENMARK Stock
- News Glenmark Pharmaceuticals Limited
- Transcript : Glenmark Pharmaceuticals Limited - Analyst/Investor Day
